VIFN.SW - Vifor Pharma AG
| Previous Close | 158.15 |
| Open | 158.30 |
| Bid | 154.00 x 0 |
| Ask | 160.00 x 0 |
| Day's Range | 155.85 - 159.40 |
| 52 Week Range | 101.80 - 164.70 |
| Volume | 199,689 |
| Avg. Volume | 163,323 |
| Market Cap | 10.301B |
| Beta (3Y Monthly) | 0.70 |
| PE Ratio (TTM) | 103.02 |
| EPS (TTM) | 1.52 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | 2.00 (1.26%) |
| Ex-Dividend Date | 2019-05-10 |
| 1y Target Est | 163.00 |
- Business Wire
Vifor Pharma and Evotec form joint venture for early development in nephrology
ST. GALLEN, Switzerland & HAMBURG, Germany-- -- Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug discovery capabilities and Vifor Pharma’s development and commercialization expertise in nephrology Joint venture will focus on patient data driven target identification ...
- Business Wire
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen
ST GALLEN, Switzerland-- -- Agreement to jointly commercialise the new diabetic kidney disease indication for INVOKANA ® in the US Only diabetes treatment indicated to slow down the progression of DKD in type 2 diabetes patients since the standard of care was developed nearly 20 years ago, while also reducing the risk of heart failure hospitalizations Using its US salesforce to promote INVOKANA ® to ...
- Business Wire
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science
Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.
- Business Wire
First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy
Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels).
- Business Wire
Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
ZURICH-- -- Veltassa ® enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190510005469/en/ Vifor Pharma today announced results from the phase-II AMBER study which demonstrated ...
- Business Wire
91st Vifor Pharma Group Annual Shareholder Meeting
ZURICH-- -- Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members of the Board of Directors standing for re-election Dividend of CHF 2.00 approved Regulatory News: At the 91 st Annual Shareholder Meeting of Vifor Pharma Ltd., shareholders approved all proposed ...
- Business Wire
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
The Vifor Pharma Group (VIFN.VX) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.